0001104659-22-010998.txt : 20220202 0001104659-22-010998.hdr.sgml : 20220202 20220202190107 ACCESSION NUMBER: 0001104659-22-010998 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220131 FILED AS OF DATE: 20220202 DATE AS OF CHANGE: 20220202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GRAY WILLIAM GARRETT CENTRAL INDEX KEY: 0001692961 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38128 FILM NUMBER: 22585454 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET, STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc. CENTRAL INDEX KEY: 0001651407 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472568632 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 212-554-4366 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 4 1 tm225237-2_4.xml FORM 4 X0306 4 2022-01-31 0 0001651407 Checkpoint Therapeutics, Inc. CKPT 0001692961 GRAY WILLIAM GARRETT 95 SAWYER RD, SUITE 110 WALTHAM MA 02453 0 1 0 0 Chief Financial Officer COMMON STOCK (RESTRICTED) 2022-01-31 4 A 0 137000 0.00 A 619170 D COMMON STOCK 2022-02-01 4 S 0 37063 2.508 D 582107 D The shares of restricted stock vest as follows: one-fourth on January 31, 2023, one-fourth on January 31, 2024, one-fourth on January 31, 2025 and one-fourth on January 31, 2026 Includes shares of restricted Common Stock, which vest over various time periods In connection with the vesting of 72,750 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Gray's tax withholding obligations. Mr. Gray had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $2.50 to $2.55. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. /s/ Garrett Gray 2022-02-02